Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
STRIDE offers a dual immunotherapy regimen with a single dose IMFINZI + IMJUDO, followed by regular interval IMFINZI monotherapy every 4 weeks for the 1L treatment of advanced or unresectable HCC:1-3
Dosing
Dose escalation or reduction is not recommended. Dose withholding or discontinuation may be required based on individual safety and tolerability1,2
Preparation
of solution
Prior to administration IMFINZI and IMJUDO must be diluted; for instructions on dilution of the medicinal products please consult 6.6 of the SmPC for IMFINZI and IMJUDIO, respectively1,2
IMFINZI and IMJUDO are both supplied as single-use vials; IMFINZI contains 500mg /10ml or 120mg / 2.4ml and IMJUDO contains 300mg / 15 ml or 25mg /1.25ml1,2
Administration
IMFINZI and IMJUDO are each administered as separate 60minute IV infusions on the same day, treatment must be initiated and supervised by physician experienced in the treatment of cancer.1,2
Infusion-related reactions with STRIDE were observed in 1.3% of patients (pooled data in 462 patients with HCC from HIMALAYA and Study 22)1,2
HCC, hepatocellular carcinoma; STRIDE, single tremelimumab regular interval durvalumab; 1L, first-line.
GB-64281 | April 2025
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
GB-74216| DOP : February 2026
